Literature DB >> 18554395

Pericardial effusion as the only manifestation of infection with Francisella tularensis: a case report.

Cécile Landais1, Pierre-Yves Levy, Gilbert Habib, Didier Raoult.   

Abstract

INTRODUCTION: Francisella tularensis, a facultative intracellular Gram-negative bacterium, has rarely been reported as an agent of pericarditis, generally described as a complication of tularemia sepsis. F. tularensis is a fastidious organism that grows poorly on standard culture media and diagnosis is usually based on serological tests. However, cross-reactions may occur. Western blotting allows the correct diagnosis. CASE
PRESENTATION: A non-smoking 53-year-old woman was admitted to hospital with a large posterior pericardial effusion. Serological tests showed a seroconversion in antibody titers to F. tularensis (IgG titer = 400) and Legionella pneumophila (IgG titer = 512). F. tularensis was identified by Western immunoblotting following cross-adsorption. The patient reported close contact with rabbits 2 weeks prior to the beginning of symptoms of pericarditis.
CONCLUSION: We report a rare case of pericardial effusion as the only manifestation of infection by F. tularensis. The etiological diagnosis is based on serology. Western blotting and cross-adsorption allow differential diagnosis.

Entities:  

Year:  2008        PMID: 18554395      PMCID: PMC2441635          DOI: 10.1186/1752-1947-2-206

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  11 in total

1.  Francisella tularensis endocarditis.

Authors:  C A Tancik; J A Dillaha
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

2.  Tularemic pericarditis; report of two cases and review of literature.

Authors:  C W ADAMS
Journal:  Dis Chest       Date:  1958-12

3.  Comparison of intuitive versus systematic strategies for aetiological diagnosis of pericardial effusion.

Authors:  Pierre-Yves Levy; Jean-Paul Moatti; Valerie Gauduchon; Francois Vandenesch; Gilbert Habib; Didier Raoult
Journal:  Scand J Infect Dis       Date:  2005

Review 4.  Tularaemia.

Authors:  A Tärnvik; L Berglund
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

Review 5.  Tularemia: a 30-year experience with 88 cases.

Authors:  M E Evans; D W Gregory; W Schaffner; Z A McGee
Journal:  Medicine (Baltimore)       Date:  1985-07       Impact factor: 1.889

6.  [Evaluation of the incidence of serological cross reactions between Legionella and Mycoplasma or Chlamydia].

Authors:  N Bornstein; J Fleurette; S Bosshard; C Bouvet; D Thouvenot; M Aymard
Journal:  Pathol Biol (Paris)       Date:  1984-03

7.  Etiologic diagnosis of 204 pericardial effusions.

Authors:  Pierre-Yves Levy; Ralf Corey; Pierre Berger; Gilbert Habib; Jean-Louis Bonnet; Samuel Levy; Thierry Messana; Pierre Djiane; Yves Frances; Celine Botta; Philippe DeMicco; Henri Dumon; Olivier Mundler; Jean-Jacques Chomel; Didier Raoult
Journal:  Medicine (Baltimore)       Date:  2003-11       Impact factor: 1.889

8.  Reduction of Brucella species and Francisella tularensis cross-reacting agglutinins by dithiothreitol.

Authors:  K A Behan; G C Klein
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

Review 9.  New approaches to diagnosis and therapy of tularemia.

Authors:  Arne Tärnvik; May C Chu
Journal:  Ann N Y Acad Sci       Date:  2007-04-27       Impact factor: 5.691

Review 10.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more
  1 in total

1.  Tularemia: A Case Series of Patients Diagnosed at the National Reference Center for Rickettsioses From 2008 to 2017.

Authors:  Anne Darmon-Curti; François Darmon; Sophie Edouard; Aurélie Hennebique; Thomas Guimard; Guillaume Martin-Blondel; Timothée Klopfenstein; Jean-Philippe Talarmin; Didier Raoult; Max Maurin; Pierre-Edouard Fournier
Journal:  Open Forum Infect Dis       Date:  2020-09-19       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.